Abstract
Willan and Eckermann describe a method for dealing with heterogeneity in value of information (VOI) calculations for prioritising and designing new research. Their article raises three fundamental (inter-related) issues for VOI methods: (1) how to make sense of the concept of uncertainty in a cost-effectiveness analysis (CEA) model, (2) the interpretation of heterogeneity in CEA, and (3) the relationship between data from a new study and the CEA model when there is heterogeneity. We discuss these three issues using an illustrative example meta-analysis of magnesium for myocardial infarction. Careful consideration of the relationship between existing (and future) evidence and the CEA model is required to provide practical VOI methods that can help research funders prioritise new research in the face of heterogeneity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
